US Patent

US7847061 — Treatment of short bowel syndrome patients with colon-in-continuity

Method of Use · Assigned to NPS Pharmaceuticals Inc · Expires 2025-11-01 · 1y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating short bowel syndrome patients with colon-in-continuity using a GLP-2 receptor agonist, such as teduglutide.

USPTO Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Drugs covered by this patent

Gattex Kit (TEDUGLUTIDE) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1320`	—	Gattex Kit

Patent Metadata

Patent number: US7847061
Jurisdiction: US
Classification: Method of Use
Expires: 2025-11-01
Drug substance claim: No
Drug product claim: No
Assignee: NPS Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.